Impax Laboratories Inc, which is said to be conducting a strategic review, named former Allergan Plc executive and industry veteran Paul Bisaro as its chief executive, sending the drugmaker’s shares soaring as much as 38 percent.
The past year has seen mounting pressure on generic drugmakers, as speedier approvals of generic products by U.S. regulators ratchet up competition in the sector, squeezing smaller players such as Impax, that lack bargaining power.
Impax has asked investment bank Morgan Stanley to help it conduct a strategic review, people familiar with the matter told Reuters earlier this month.
Bisaro, 56, was largely behind transforming a much smaller generic drugmaker Watson Pharmaceuticals, at a couple of billion dollars in market cap, into the current version of Allergan with a market valuation of about $80 billion.
Given some of Impax’s near-term challenges and Bisaro’s still relatively young age, Leerink analysts believe he is committing to a process that may not be short-term.
However, the hire and the Reuters report suggest Impax will be an active acquirer or future M&A target, Leerink said.
Bisaro, whose appointment is effective immediately, succeeds Kevin Buchi, who has served as interim president and chief executive since December.
“Bisaro is one of a handful of experienced generic industry executives we have gotten to know over the past 18 years that has demonstrated a solid track record of execution,” BTIG analysts said, raising their price target to $16 from $13.
Impax’s shares were up 38.65 percent at $12.83, set for their best day in more than 8 years.
By Ankur Banerjee
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.